[Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].

CONCLUSION: In this small but prospective clinical study no increased risk for cardiovascular events during the upload phase of the VEGF inhibitors ranibizumab and bevacizumab could be detected when taking the age and pre-existing cardiovascular diseases into consideration. PMID: 26801323 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26801323?dopt=Abstract

Source: Der Ophthalmologe - January 22, 2016 Category: Opthalmology Authors: Fischer C, Schäfer K, Dschietzig T, Hoerauf H Tags: Ophthalmologe Source Type: research